文献速递外周动脉疾病

外周动脉疾病下肢血运重建后抗血栓处方差异及延长氯吡格雷治疗的评价

Variations in antithrombotic prescriptions and evaluation of extended clopidogrel therapy after lower extremity revascularization for peripheral artery disease.
PubMed 文献 · J Vasc Surg · 2025-03-22

本研究回顾性分析1954例外周动脉疾病下肢血运重建患者的电子病历,发现围术期有17种、长期随访有101种抗血栓组合,氯吡格雷最常用(69.8%)。延长氯吡格雷治疗(>12个月)与改善生存相关,且不增加出血。

要点

  • 围术期抗血栓组合达17种,长期随访达101种,提示真实世界处方差异大。
  • 氯吡格雷最常用(69.8%),其中69.5%接受延长治疗(>12个月)。
  • 延长氯吡格雷治疗与改善生存相关,且不增加出血。

核心结论

  • 延长氯吡格雷治疗与改善生存相关,且不增加出血。
  • 观察性抗血栓研究受处方模式广泛变异及影响因素限制,需前瞻性随机试验验证。

研究设计与样本

  • 回顾性分析三级医疗中心1954例外周动脉疾病下肢血运重建患者的电子病历,由药师提取抗血栓处方。
  • 比较延长氯吡格雷治疗(>12个月)与有限治疗(≤12个月)患者的围术期及长期结局。

主要发现

  • 共1954例患者接受17种围术期抗血栓组合,长期随访出现101种组合。
  • 氯吡格雷最常用,占69.8%(n=1363);其中69.5%(n=947)接受延长治疗(>12个月)。
  • 延长治疗组既往腔内手术比例更高(21.8% vs 15.2%;P=.005);有限治疗组年龄更大(72岁 vs 69岁;P<.001),充血性心力衰竭(21% vs 14%;P=.001)和慢性肾功能不全(22.2% vs 15.6%;P<.004)比例更高。
  • 延长治疗组因间歇性跛行治疗比例更高(57.5% vs 46.1%;P<.001),但血运重建策略无差异。
  • Kaplan-Meier曲线显示延长氯吡格雷治疗组总生存、无MALE生存和无MACE生存显著更高,无MALE或无MACE生存无差异。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 观察性研究受抗血栓治疗广泛变异及影响处方模式的因素限制,这些因素只能在前瞻性随机试验中调和。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: The optimal antithrombotic combination and duration after open surgical or endovascular lower extremity revascularization (LER) in patients with peripheral arterial disease (PAD) lacks consensus. This study examines the variability of antithrombotic prescriptions in a tertiary care center, highlighting challenges in related research. The durations of the various prescriptions were captured, and this study focused on studying the impact of duration of clopidogrel therapy on patient outcomes. METHODS: The electronic medical records of patients with PAD undergoing LER were reviewed. All antithrombotic prescriptions after initial LER were abstracted by pharmacists. Demographics and clinical characteristics of patients who received clopidogrel after initial LER were evaluated. A comparison of patients who received extended clopidogrel therapy (>12 months) compared with limited clopidogrel therapy (≤12 months) was performed. Perioperative and long-term outcomes were compared and analysis focused on major adverse limb events (MALEs), major adverse cardiac events (MACEs), and mortality. RESULTS: A total of 1954 patients received 17 different perioperative antithrombotic combinations and 101 combinations over long-term follow-up. Clopidogrel was the most commonly used medication in 69.8% (n = 1363). Among patients treated with clopidogrel after LER, 69.5% (n = 947) received extended therapy (>12 months). Patients who received extended clopidogrel therapy were more likely to have had a prior endovascular procedure (21.8% vs 15.2%; P = .005); those who received limited therapy (≤12 months) were older (72 years vs 69 years; P < .001) and more likely to have congestive heart failure (21% vs 14%; P = .001) and chronic renal insufficiency (22.2% vs 15.6%; P < .004). Patients in the extended therapy group were more likely to be treated for claudication (57.5% vs 46.1%; P < .001) compared with patients with limited therapy, but there was no difference in revascularization strategies. Kaplan-Meier curves showed significantly higher overall survival, MALE-free survival, and MACE-free survival in patients with extended clopidogrel therapy without difference in freedom from MALE or MACE. Cox regression demonstrated independent association of limited clopidogrel therapy with mortality (hazard ratio [HR], 1.93; 95% confidence interval [CI], 1.6-2.31), mortality or MALE (HR, 1.32; 95% CI, 1.14-1.53), and mortality or MACE (HR, 1.39; 95% CI, 1.2-1.62). The duration of clopidogrel therapy was not associated with bleeding. CONCLUSIONS: The number of unique prescription combinations found in this study highlights real-world variations in antithrombotic therapy after revascularization for patients with PAD. Extended clopidogrel therapy was associated with improved survival compared with limited therapy in this analysis without an increase in bleeding. Observational studies of antithrombotic therapy are limited by extensive variations and factors affecting prescription patterns that can only be reconciled in prospective randomized trials.

来源:J Vasc Surg,查看原文。版权归原作者所有。

引用

  1. Wells N, Alameddine D, Dhanda U, et al. Variations in antithrombotic prescriptions and evaluation of extended clopidogrel therapy after lower extremity revascularization for peripheral artery disease. J Vasc Surg. 2025. PMID: 40122313. doi:10.1016/j.jvs.2025.03.183

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。